Tell me again why anyone thinks this stuff works.-Avii
Well, it's on target to beat Optune on survival, datapoint for datapoint, though we obviously don't have arm by arm comparisons yet. -LF95
The Optune trial enrolled patients who had a biopsy only. And I'm pretty sure they didn't have a steroid exclusion criteria.
Cross trial comparisons for time to event endpoints (like OS) are fraught with uncertainties. Nothing wrong with trying but you can easily fool yourself (that's why the FDA does not allow it for a claim of substantial evidence of efficacy)
Market Data 
Markets 
AI
